InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,467.60
(
0.28%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
83.58
(
0.54%
)
Bitcoin
64,285.91
(
0.45%
)
Post# of 251721
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119569
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: WorstLuck post# 183041

Tuesday, 10/21/2014 12:38:13 PM

Tuesday, October 21, 2014 12:38:13 PM

Post# of 251721
ENTA—Your $3.0B forecast of annual US/EU sales for the 3-DAA regimen is the cause of the discrepancy I was inquiring about. My number, which is based on the pricing and volume-share assumptions in the model, is $4.1B.

The $4.1B figure comes from summing 55K EU patients paying an average price of $25K ($1.38B) and 45K US patients paying an average price of $60K ($2.70B).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up